Lexicon Genetics Incorporated has extended its OmniBank Universal agreement with Boehringer Ingelheim Pharmaceuticals Inc. Under the terms of the agreement, Boehringer Ingelheim will continue its access to Lexicon's OmniBank library through February 2004. Boehringer Ingelheim will also continue to have access to gene knockouts generated under Lexicon's patented gene targeting technologies with genetic alterations directed at specific drug targets of interest, and access to drug target validation data generated by Lexicon for specified targets. Financial terms of the arrangement were not disclosed.

Lexicon Genetics Incorporated is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is using gene knockout technology to systematically discover the physiological functions and medical uses of genes.

The Company's gene function discoveries fuel therapeutic discovery programs in cardiovascular disease, diabetes, obesity, immune disorders, neurological disease and cancer. Lexicon has established drug discovery alliances and functional genomics collaborations with leading pharmaceutical and biotechnology companies, research institutes and academic institutions throughout the world to commercialize its technology and further develop its discoveries.